Page 1 2 ... 30 40 50 ... 200 ... NEXT>>
[ October 20, 2014 | Author: admin | Views: 73158 | Weather: | Mood: normal]

Even given some of the good news coming out of the gold sector recently including dovish comments from the Fed and positive news from both Newmont Mining (NYSE: NEM  ) and Gold Fields (NYSE: GFI  ) Barrick Gold (NYSE: ABX  ) has been unable to avoid further delays at Pascua-Lama. The stock has traded higher along with its peers, but investors should still maintain a cautious view. When complete, the mine is expected to be the largest gold mine in the world, which will only be meaningful when it is functional. ABX data by YCharts In the video below, Fool.com contributor Doug Ehrman discusses the delay and what it could mean for the company. Looking beyond this single project, gold has outshined the stock market with strong returns since 2000, but more recently has given way to big declines. The Motley Fool’s new free report, “The Best Way to Play Gold Right Now,” … Continue reading

[ October 20, 2014 | Author: admin | Views: 31076 | Weather: | Mood: normal]

The Utica Shale remains a bit of an enigma for drillers and investors alike. Some see it as the next big thing, while others are cautiously backing away. One thing is for sure: For many drillers, the Utica Shale isn’t living up to the original sky-highexpectations, especially for oil content. The lack of oil is one of reasons why bothChesapeake Energy (NYSE: CHK  ) and Devon Energy (NYSE: DVN  ) are planning on selling their Utica assets after initially building a sizable presence. Chesapeake, which is the largest Utica leaseholder, just put around 100,000 of its acres up for sale. While that’s a small portion of its overall acreage in the play it is worth noting because it marks a continued trend from the company, which also sold a large stake in the Utica last year to Total. Devon is taking things one step further; it’s attempting to unload the rest of … Continue reading

[ October 20, 2014 | Author: admin | Views: 88317 | Weather: | Mood: normal]

Charles Schwab (SCHW) reported a 17% jump in third-quarter profits to $290 million on Tuesday, while its earnings of $0.22 per share topped Wall Street estimates by $0.02. Its revenue jump of 15% to nearly $1.4 billion represented a 13-year record for the firm. Plus, the firm says it anticipates sales growth to outpace costs by 3%-5% next year. The company’s client results “supported double-digit percentage increases in all three of our main revenue sources and 15% overall revenue growth versus the year-ago quarter,” according to CEO Walt Bettinger. “Even with the continued headwind created by an interest rate environment that remains at historic lows, our third-quarter revenues surpassed all our prior quarterly results save the extraordinary spike we experienced at the height of the Internet bubble,” Bettinger said in a statement. In the second quarter, the brokerage group saw its sales rise just 4% to $1.34 billion, while expenses … Continue reading

[ October 20, 2014 | Author: admin | Views: 9196 | Weather: | Mood: normal]

On Friday, small cap pharma stock Apricus Biosciences Inc (NASDAQ: APRI) jumped just over 10% and not onlydid the stock hold onto those gains, it madeanother 10% jumps on Monday meaning its time to take a closer look at the stock along with the performance of other potential benchmarks in the sexual health or reproductive health spaces like The Female Health Company (NASDAQ: FHCO) and Repros Therapeutics Inc (NASDAQ: RPRX). What is Apricus Biosciences Inc? Small cap Apricus Biosciences is a pharmaceutical company that develops and markets through its licensing partners innovative treatments that have the potential to help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. Apricus Biosciences has one approved product called Vitaros – atopically-applied cream formulation for the treatment of erectile dysfunction. Vitaros is now approved in Europe and Canada and will be commercialized by Apricus’ marketing partners,including include Abbott Laboratories … Continue reading

[ October 20, 2014 | Author: admin | Views: 25992 | Weather: | Mood: normal]

Kia offered a teaser photo this week of the look of the “an all-new midsize multi-purpose vehicle” that it will unveil at the New York Auto Show later this month in a photo Thursday. The description appears to be Kia’s code for “our new minivan.” If you look closely, you can see the rear door handle for a slider just behind the front handle. As its Sedona minivan aged, Kia kept saying that there would be a successor, that it was not going to just kill it and get out of the segment. As others did leave the slow-growing minivan market — GM, Ford, Hyundai, Chrysler heading to a single model — we had our doubts. And Kia sold just 7,079 Sedonas last year, down 60% from 17,512 in 2012. But here “it” is (we suspect it may get a new name along with the new design): “This global debut … Continue reading